Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY).

Myeloproliferative Neoplasm Clinical Trial

— PROPHECY  

Official title:

Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY): A GIMEMA Observational Registry for Italian MPN Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04378855
• Other study ID #: GIMEMA QoL-MPN 0118
• Status: Not yet recruiting
• Start date: May 2020
• Est. completion date: May 2025

Study information

• Verified date: May 2020
• Source: Gruppo Italiano Malattie EMatologiche dell'Adulto
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study will ultimately aim at developing a GIMEMA platform for collecting HRQoL and symptom burden information on Italian patients with Philadelphia chromosome negative MPN. The main objective of the protocol is to improve our understanding of the impact of the disease and various treatments on patients-wellbeing, symptom burden and daily functioning.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 576
• Est. completion date: May 2025
• Est. primary completion date: May 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients diagnosed with Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (pre-PMF, overt-PMF) and post-ET/post-PV Myelofibrosis (MF), (i.e. Philadelphia chromosome negative myeloproliferative neoplasm (MPN)) according to 2016 WHO classification.

• Known IPSS/IPSET/DIPSS risk score category at time of initial diagnosis of PV, ET and PMF, respectively.

• Initial diagnosis of MPN within one year before date of registration.

• Having a full baseline PRO Evaluation completed.

• Adult patients (= 18 years old).

• Written informed consent provided.

Exclusion Criteria:

• Having any kind of psychiatric disorder or major cognitive dysfunction problems hampering a self-reported evaluation.

• Not able to read and understand local language (i.e. Italian).

Related Conditions & MeSH terms

• Myeloproliferative Disorders
• Myeloproliferative Neoplasm
• Neoplasms

Intervention

Other:
• Questionnaire
Quality of life assessment

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Gruppo Italiano Malattie EMatologiche dell'Adulto

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Compare HRQoL profiles of Philadelphia chromosome negative MPN patients with those of their peers in the general population	To detect a baseline difference of at least 4 points between MPN patients and their peers in the general population in any of the following primary scales of the EORTC QLQ-C30 questionnaire: fatigue, global QoL/health status, physical, emotional and role functioning (all ranging from 0 to 100 points).	After 5 years from study entry
Secondary	Compare HRQoL profiles of Philadelphia chromosome negative MPN patients with those of their peers in the general population	The same comparisons described for the primary endpoint will be performed on all other scales from EORTC QLQ-C30 questionnaire.	After 5 years from study entry
Secondary	Compare HRQoL profiles of Philadelphia chromosome negative MPN patients with those of their peers in the general population	The same comparisons described for the primary endpoint will be performed on all other scales from FACIT-Fatigue questionnaire.	After 5 years from study entry
Secondary	MPN patients' baseline profiles of self-reported HRQoL	To report MPN patients' baseline profiles of self-reported HRQoL and symptoms scores.	After 5 years from study entry
Secondary	Prognostic value, on overall survival and other clinical outcomes, of baseline patients' self-reported fatigue	To investigate the prognostic value of baseline patients' self-reported fatigue from EORTC QLQ-C30	After 5 years from study entry
Secondary	Prognostic value, on overall survival and other clinical outcomes, of baseline patients' self-reported HRQoL	To investigate the prognostic value of baseline patients' self-reported HRQoL	After 5 years from study entry
Secondary	Relationship between pruritus and HRQoL.	To investigate the relationship between Pruritus as assessed by MPN-SAF TSS questionnaire and HRQoL.	After 5 years from study entry
Secondary	Patterns over time of HRQoL	To estimate and compare patterns over time of HRQoL (outcome measures: EORTC QLQ-C30, FACIT-Fatigue, MPN-SAF TSS and FACIT-TS-G) of PT, EV and PMF patients.	After 5 years from study entry
Secondary	Prognostic patient-based index	To devise a prognostic patient-based index.	After 5 years from study entry
Secondary	Physicians' and patients' preferences for involvement in treatment decision-making	To assess physicians' and patients' preferences for involvement in treatment decision-making, as assessed by the CPS Questionnaire, across different risk groups and examine relationships between preferences for involvement and patient characteristics.	After 5 years from study entry
Secondary	Relationship between self-reported satisfaction with care with other HRQoL outcomes.	To investigate the relationship, in MPN patients, between self-reported satisfaction with care as assessed by the FACIT-TS-G questionnaire and its relationship with other HRQoL outcomes.	After 5 years from study entry